Here are the 10-K annual reports from Arrowhead Research Corporation (ARWR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ARWR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARWR filings page.
Arrowhead Pharmaceuticals (ARWR) reported fiscal 2026 revenue of $450.8 million, down from $829.4 million in fiscal 2025 as lower collaboration and license revenue outweighed initial REDEMPLO sales. Net loss was $724.2 million, versus $1.6 million, including a $215.0 million expense for a priority review voucher purchased in September.
REDEMPLO generated $6.6 million in product revenue. In Phase 3 SHASTA-3 and SHASTA-4 studies for severe hypertriglyceridemia, plozasiran produced median triglyceride reductions of 79% and 81%, respectively, at Month 12; a prespecified pooled analysis also found significantly fewer acute pancreatitis events. Arrowhead submitted an sNDA and said a potential U.S. launch is planned for Q2 2027, pending regulatory filing, review and approval. After year-end, the FDA accepted the planned application into its STAR pilot program, whose accepted applications qualify for six-month priority review. Arrowhead withdrew its notice to use the PRV and continues to hold it.
At September 30, 2026, cash, cash equivalents and restricted cash were $62.7 million, and available-for-sale securities were $1.13 billion. Operating activities used $271.9 million in cash. Management expects current resources and its operating plan to fund operations through at least 12 months from the financial statements’ issuance.
Arrowhead Pharmaceuticals (ARWR) files its annual report describing a transition from a pure R&D biotech to a commercial-stage RNA interference company. The business centers on its proprietary TRiM platform, which uses targeted siRNA to silence disease-causing genes across multiple tissues.
A major milestone is the 2025 FDA approval and U.S. commercial launch of REDEMPLO (plozasiran) for adults with Familial Chylomicronemia Syndrome, the first and only FDA‑approved siRNA studied in both genetically confirmed and clinically diagnosed FCS patients. The company is running fully enrolled Phase 3 studies in severe hypertriglyceridemia and plans a supplemental NDA in 2026.
Arrowhead reports 18 company-discovered drug candidates in clinical trials, spanning cardiovascular, liver, obesity, renal, pulmonary, CNS and rare neuromuscular diseases, plus a discovery pipeline. It highlights extensive collaborations with GSK, Takeda, Amgen, Sarepta and Novartis that can generate milestones and royalties, and an IP estate of about 643 issued patents and roughly 833 pending applications worldwide.
Arrowhead Pharmaceuticals amended its annual report to disclose a major collaboration with Sarepta Therapeutics and results for fiscal 2024. The company expects to receive $500.0M upfront in cash plus $325.0M as an equity investment and $250.0M in five annual installments, with an additional near-term $300.0M payment opportunity and up to $10.0B in future milestones and tiered royalties. Arrowhead sold 11,926,301 shares to Sarepta at $27.25 per share for approximately $325.0M.
Pipeline and platform highlights include advancement of multiple RNAi programs (ARO-INHBE, ARO-ALK7, ARO-DM1, ARO-C3, ARO-CFB, ARO-RAGE and others) with Phase 1/2a filings and Phase 2/3 results for cardiometabolic candidates. Financially, fiscal 2024 revenue was $3.6M, net loss was $599.5M (diluted loss per share ($5.00)), and cash and investments totaled $681.0M at September 30, 2024.